Cargando…

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report

BACKGROUND: Immune checkpoint inhibitors have revolutionized treatment and improved survival in many cancers. However, since immune-related adverse events (irAEs) are potentially fatal, early recognition and prompt treatment are warranted. One of the rarest but most dramatic irAE is myocarditis, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monge, Cecilia, Maeng, Hoyoung, Brofferio, Alessandra, Apolo, Andrea B., Sathya, Bharath, Arai, Andrew E., Gulley, James L., Bilusic, Marijo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299503/ https://www.ncbi.nlm.nih.gov/pubmed/30563577 http://dx.doi.org/10.1186/s40425-018-0473-0

Ejemplares similares

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Nivolumab-associated acute glomerulonephritis: a case report and literature review
por: Jung, Kyungsuk, et al.
Publicado: (2016)

Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
por: Mandl, Stefanie J, et al.
Publicado: (2014)

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
por: Gulley, James L., et al.
Publicado: (2019)

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report
por: Pastor, Danielle M., et al.
Publicado: (2020)

Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy
por: Lucas, Julie L., et al.
Publicado: (2017)

Catheter‐related right atrial thrombus in sickle cell disease
por: Zhao, Chen, et al.
Publicado: (2017)

Nivolumab‐induced fatal myocarditis: A case report
por: Bharathidasan, Kavya, et al.
Publicado: (2023)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
por: Fukasawa, Yoko, et al.
Publicado: (2017)

Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature
por: Matsuo, Keisuke, et al.
Publicado: (2019)

Anti-angiogenesis in prostate cancer: knocked down but not out
por: Bilusic, Marijo, et al.
Publicado: (2014)

Ipilimumab/nivolumab/tozinameran: Acute myocarditis: 3 case reports
Publicado: (2022)

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
por: Peinetti, Nahuel, et al.
Publicado: (2022)

Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021)

Symptomatic Myocarditis Post COVID-19 Vaccination
por: Patel, Palak, et al.
Publicado: (2022)

Ipilimumab/nivolumab: Myocarditis-myositis overlap syndrome and ocular myositis: case report
Publicado: (2020)

Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report
por: Delombaerde, Danielle, et al.
Publicado: (2022)

An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
por: Naganuma, Ken, et al.
Publicado: (2022)

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
por: Tay, Rebecca Y, et al.
Publicado: (2017)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
por: Kim, Joseph W., et al.
Publicado: (2012)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2020)

A Phase I Trial of Pox PSA vaccines (PROSTVAC(®)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
por: DiPaola, RS, et al.
Publicado: (2006)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer
por: Komatsu, Masaru, et al.
Publicado: (2021)

Efficacy and immune-related adverse event associations in avelumab-treated patients
por: Kelly, Karen, et al.
Publicado: (2020)

Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management
por: Yanase, Takahiro, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report
por: Lie, Gabrielle, et al.
Publicado: (2020)

Strategies for developing and optimizing cancer vaccines
por: Maeng, Hoyoung M., et al.
Publicado: (2019)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

(18)F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
por: Lim, Ilhan, et al.
Publicado: (2019)

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
por: Bilusic, Marijo, et al.
Publicado: (2022)

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges
por: Martin Huertas, Roberto, et al.
Publicado: (2019)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
por: Hantel, Andrew, et al.
Publicado: (2018)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
por: Nakamura, Mikako, et al.
Publicado: (2023)

Pseudo-Progression of Melanoma Treated with Nivolumab/Ipilimumab: A Case Report
por: Velazquez, Adan Martin Cuevas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n474e4q8to00lu9u4o4erse5dq